StreetInsider.com News Articles

Form 10-K AMARIN CORP PLC\UK For: Dec 31

Mon, 02 Mar 2026 17:31:00 -0500

http://archive.fast-edgar.com/20260302/AE2Z4G2CZZ2RCZZK22ZN2ZYKJ4ANZZ22ZI8G

Filed on: March 2, 2026

Form 10-K AMARIN CORP PLC\UK For: Dec 31

Mon, 02 Mar 2026 17:31:00 -0500

http://archive.fast-edgar.com/20260302/AE2Z4G2CZZ2RCZZK22ZN2ZYKJ4ANZZ22ZI8G

Filed on: March 2, 2026

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

Mon, 02 Mar 2026 08:00:00 -0500

Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden

DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

Mon, 02 Mar 2026 08:00:00 -0500

Amarin Corp. (AMRN) Reports In-Line Q4 EPS

Wed, 25 Feb 2026 07:22:55 -0500

Amarin Corp. (NASDAQ: AMRN) reported Q4 EPS of $0.00. Revenue for the quarter came in at $49.2 million.

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.

Form 8-K AMARIN CORP PLC\UK For: Feb 25

Wed, 25 Feb 2026 07:05:00 -0500

si-local-file:///var/storage/secattach/20260225/26055205.html

Form 8-K AMARIN CORP PLC\UK For: Feb 25

Wed, 25 Feb 2026 07:05:00 -0500

si-local-file:///var/storage/secattach/20260225/26055205.html

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 07:00:00 -0500

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies

Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise

Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge
Supported in 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 07:00:00 -0500

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies

Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise

Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge
Supported in 2025

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Mon, 23 Feb 2026 08:00:00 -0500

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized.

Despite decades of scientific advances and clear guideline recommendations, millions of patients at high risk for CVD remain untreated or undertreated. The

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Mon, 23 Feb 2026 08:00:00 -0500

Despite decades of scientific advances and clear guideline recommendations, millions of patients at high risk for CVD remain untreated or undertreated. The

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

Wed, 11 Feb 2026 08:00:00 -0500

DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Information on how to participate is as follows.

Access to the live call:

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

Wed, 11 Feb 2026 08:00:00 -0500

Information on how to participate is as follows.

Access to the live call:

Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Fishman Peter L.